Paris-based Arterial Remodeling Technologies (ART) plans to reveal for the first time details of the design of its polymer-based biodegradable stent. Company co-founder Dr. Antoine LaFont will also ...

Reva Medical has returned, raising $45 million to complete its work in the historically difficult market of bioresorbable stents. The California-based outfit went through Chapter 11 bankruptcy ...

On Tuesday, FDA announced that it has approved the first bioresorbable polymer stent, a development bound to spur competition between Abbott that makes the device and Boston Scientific that makes a ...

A study, published in The New England Journal of Medicine, compared drug-eluting bioresorbable vascular scaffolds with drug-eluting metallic stents in percutaneous coronary interventions. Abbott ...

The Svelte stent, designed to facilitate direct stenting and transradial access in percutaneous coronary intervention (PCI), did not differ significantly from metallic everolimus-eluting stents with ...

First-generation bioresorbable vascular scaffolds (BVS) may be just as effective as drug-eluting metallic stents, which are currently the standard treatment for heart disease patients undergoing ...

Please provide your email address to receive an email when new articles are posted on . There were small increases in target lesion failure and device thrombosis within 3 years with a bioresorbable ...

New York, May 07, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Bioabsorbable Stent/Bioresorbable Scaffold Industry" - https ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window PARIS -- ...

Abbott has delivered new, longer-term data from a clinical study of its dissolving stent for severe peripheral artery disease located below the knee, following the implant’s approval by the FDA ...

According to MarketsandMarkets™, the Interventional Cardiology Devices Market is projected to grow from about USD 31.12 ...

SYDNEY, Australia and SAN DIEGO, Feb. 25, 2011 (GLOBE NEWSWIRE) -- REVA Medical, Inc. (ASX:RVA) ("REVA" or the "Company"), which is developing a novel bioresorbable slide and lock drug-eluting ...